Naringin inhibited endothelial inflammation, oxidative stress, and degradation of tight junction proteins, such as ZO-2, OCLN, and vascular endothelial-cadherin. Furthermore, it promoted NO release, thereby restoring the functional and structural integrity of the endothelium and inactivating MAPK signaling. The gene discussed is TJP2; the disease is inflammation.